Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.93% | -13.09% | 25.23% | -55.57% | 8.49% |
| Total Depreciation and Amortization | -2.60% | 7.78% | -9.57% | 1.97% | 1.85% |
| Total Amortization of Deferred Charges | -- | -- | -33.61% | -- | -- |
| Total Other Non-Cash Items | 67.85% | 59.26% | -20.89% | 135.06% | -61.36% |
| Change in Net Operating Assets | 157.21% | -74.73% | 60.08% | 24.22% | -3.74% |
| Cash from Operations | 113.48% | -302.22% | 161.44% | -108.33% | -143.06% |
| Capital Expenditure | -- | 20.27% | -72.90% | 74.28% | 52.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 380.07% | 105.53% | -- | -- |
| Cash from Investing | -- | 468.99% | 104.50% | -4,351.08% | 52.46% |
| Total Debt Issued | -- | -- | -67.15% | 59.23% | -- |
| Total Debt Repaid | 69.50% | -279.15% | 70.65% | -1,161.40% | 72.20% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 90.00% | -344.44% | 95.87% | -- | -- |
| Cash from Financing | 70.74% | -281.68% | -90.84% | 299.33% | 715.46% |
| Foreign Exchange rate Adjustments | -81.65% | 173.87% | -163.02% | 269.18% | -264.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.64% | -228.73% | 192.14% | -551.30% | 58.30% |